What Carbogen Amcis does

Carbogen Amcis is a Swiss pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Bubendorf, Switzerland, founded in 1987 and operating as a wholly-owned subsidiary of Dishman Carbogen Amcis Limited (India) since 2006. The company provides integrated drug substance and drug product services to pharmaceutical and biopharmaceutical customers, spanning non-GMP development, clinical and commercial API manufacturing, sterile injectable drug product manufacturing, and specialty chemicals (vitamin D analogs and cholesterol/lanolin derivatives). It operates eight manufacturing sites across Switzerland, the United Kingdom, France, the Netherlands, and China, with more than 2,000 employees globally.

The company's technology platform centers on specialized capabilities including highly potent API manufacturing down to 0.05µg/m3 OEL using barrier isolation technology, antibody drug conjugate (ADC) bioconjugation services, Simulated Moving Bed chromatography refined over 20 years, flow chemistry, crystallization process development, and Annex 1-compliant sterile drug product manufacturing including lyophilization. Reactor capacity ranges from 1L laboratory scale to 6,300L commercial production. The company maintains consistent clean inspection records across FDA, Swissmedic, NMPA, ANSM, ANVISA, and ISO 22716 audits across all major sites.

Carbogen Amcis operates a B2B, project-based professional services model with typical payment milestones structured as 40% on order acceptance, 50% on service completion, and 10% on report delivery. Revenue is generated through direct enterprise engagement with pharmaceutical and biopharmaceutical customers across horizontal segments (drug substance, drug product, specialty chemicals), supported by co-investment agreements with select anchor clients. The company goes to market through direct sales and account management, industry conference presence (CPhI, BIO-Europe, ChemOutsourcing, ISPE), and content marketing via its knowledge center, with no third-party distribution channels.

Name

Carbogen Amcis

Legal name

CARBOGEN AMCIS AG

Website

https://carbogen-amcis.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Contract pharmaceutical manufacturing
• API development services
• Sterile drug product manufacturing
• Highly potent API manufacturing
• Antibody drug conjugate services

Headquarters

HQ city

Bubendorf

HQ country

Switzerland

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: CDMO services for drug substance and drug product development and manufacturing, including clinical and commercial API production, sterile drug product manufacturing, and analytical services. Revenue generated through project-based contracts, typically with upfront payments (40%), milestone payments (50%), and final payments (10%) upon delivery of reports.
2. Specialty Chemicals (Vitamin D and Cholesterol): Production and sale of Vitamin D analogs, Vitamin D2, cholesterol, and lanolin derivatives for pharmaceutical, cosmetic, food supplement, and industrial applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Carbogen Amcis is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing integrated drug substance (API) and drug product development and manufacturing services. It serves pharmaceutical and biopharmaceutical companies with capabilities spanning non-GMP and GMP API manufacturing, sterile injectable drug product manufacturing, highly potent compound handling, ADC/bioconjugation, and specialty Vitamin D and cholesterol products, across 8 manufacturing sites in Europe and China.

Product overview

CARBOGEN AMCIS is a Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services from drug substance to drug product. The portfolio consists of three core service pillars: Drug Substance CDMO (API development and manufacturing), Sterile Drug Product CDMO (injectable drug manufacturing), and Cholesterol & Vitamin D Specialities. Supporting these core areas are specialized capability modules including SPRINT early-phase services, Highly Potent API manufacturing, ADC & Bioconjugation, Chromatography, Flow Chemistry, and Crystallization. The company operates 8 manufacturing sites across Switzerland, UK, France, Netherlands, and China, providing services from gram-scale development through commercial production up to multi-tonne scale.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Substance CDMO Services
• Sterile Drug Product CDMO Services
• SPRINT Early-Phase Development Services
• Highly Potent API (HiPo) Manufacturing
• ADC & Bioconjugation Services
• Vitamin D Analogs and Vitamin D2
• Cholesterol and Lanolin Derivatives

Quantifiable outcome

• Successful completion of unannounced NMPA GMP inspection with no observations identified at Shanghai facility
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

One partnership is on record.

• Celonic GroupcoreStrategic or Co-development Partner · 27 October 2025Strategic alliance between Celonic Group and CARBOGEN AMCIS AG to develop and manufacture antibody drug conjugates (ADCs). The partnership aims to create an integrated ADC development platform amid rising demand, leveraging their respective expertise and expanding infrastructure to improve speed and quality.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

Broad incumbents

• Eurofins CDMO (formerly Alpharma/IIT Research Institute): Global contract services group with CDMO capabilities spanning API development, HPAPI, and drug product services. Comparable as a broader-incumbent CDMO with overlapping capabilities but operating as part of a much larger diversified testing/services platform.
• Lonza: Swiss-headquartered global CDMO leader with massive small-molecule API, biologics, and cell-and-gene therapy manufacturing footprint. Comparable as a larger Swiss CDMO operating across overlapping modalities, but orders of magnitude larger and serving biotech as well as big pharma.

Direct peers

• Sterling Pharma Solutions: UK-headquartered CDMO specializing in small-molecule API development and HPAPI manufacturing. Closely comparable on UK-based HPAPI operations and overlap with Carbogen's Manchester site.
• Recipharm: European CDMO offering integrated drug substance and drug product services including sterile fill-finish. Comparable as a multi-site European CDMO targeting pharma customers with similar project-based service model.
• WuXi STA (WuXi AppTec): China-based large-scale CDMO subsidiary of WuXi AppTec offering end-to-end small-molecule API and drug product services. Comparable as a CDMO peer of similar integrated scope with significant Asian manufacturing capacity overlapping Carbogen's Shanghai presence.
• Piramal Pharma Solutions: Indian-headquartered CDMO with strong HPAPI and ADC capabilities across global sites. Comparable on HPAPI specialization, ADC services, and Indian ownership/operational heritage similar to Dishman Carbogen Amcis.
• Aenova Group: German CDMO providing solid dosage forms, sterile fill-finish, and API services for pharma customers. Comparable as a mid-sized European integrated CDMO serving similar big-pharma customer base.
• Hovione: Privately-held Portuguese CDMO specializing in API development, HPAPI handling, and particle engineering. Closely comparable on specialty HPAPI capabilities, integrated drug substance-drug product services, and family-owned private ownership profile.
• Siegfried Holding: Swiss-headquartered integrated small-molecule CDMO with drug substance and drug product services across multiple global sites. Most directly comparable peer given shared Swiss heritage, integrated DS+DP model, and similar enterprise-scale customer mix.
• Cambrex: US-based small-molecule API CDMO acquired by Permira. Directly comparable on small-molecule API development, HPAPI capabilities, and analytical services for pharma clients across clinical and commercial stages.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• Xx.com/CARBOGEN_AMCIS

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carbogen Amcis